|
1
|
Konturek A, Barczyński M, Stopa M and
Nowak W: Trends in Prevalence of Thyroid Cancer Over Three Decades:
A Retrospective Cohort Study of 17,526 Surgical Patients. World J
Surg. 40:538–544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van der Zwan JM, Mallone S, van Dijk B,
Bielska-Lasota M, Otter R, Foschi R, Baudin E and Links TP;
RARECARE WG, : Carcinoma of endocrine organs: Results of the
RARECARE project. Eur J Cancer. 48:1923–1931. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miller KD, Goding Sauer A, Ortiz AP,
Fedewa SA, Pinheiro PS, Tortolero-Luna G, Martinez-Tyson D, Jemal A
and Siegel RL: Cancer Statistics for Hispanics/Latinos, 2018. CA
Cancer J Clin. 68:425–445. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lin P, Guo YN, Shi L, Li XJ, Yang H, He Y,
Li Q, Dang YW, Wei KL and Chen G: Development of a prognostic index
based on an immunogenomic landscape analysis of papillary thyroid
cancer. Aging (Albany NY). 11:480–500. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zarkesh M, Zadeh-Vakili A, Akbarzadeh M,
Fanaei SA, Hedayati M and Azizi F: The role of matrix
metalloproteinase-9 as a prognostic biomarker in papillary thyroid
cancer. BMC Cancer. 18:11992018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Carling T and Udelsman R: Thyroid cancer.
Annu Rev Med. 65:125–137. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin P, He Y, Wen DY, Li XJ, Zeng JJ, Mo
WJ, Li Q, Peng JB, Wu YQ, Pan DH, et al: Comprehensive analysis of
the clinical significance and prospective molecular mechanisms of
differentially expressed autophagy-related genes in thyroid cancer.
Int J Oncol. 53:603–619. 2018.PubMed/NCBI
|
|
9
|
Liu C, Su C, Chen Y and Li G: miR-144-3p
promotes the tumor growth and metastasis of papillary thyroid
carcinoma by targeting paired box gene 8. Cancer Cell Int.
18:542018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Acquaviva G, Visani M, Repaci A, Rhoden
KJ, de Biase D, Pession A and Giovanni T: Molecular pathology of
thyroid tumours of follicular cells: A review of genetic
alterations and their clinicopathological relevance.
Histopathology. 72:6–31. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Riesco-Eizaguirre G and Santisteban P:
Molecular biology of thyroid cancer initiation. Clin Transl Oncol.
9:686–693. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
DeLellis RA: Pathology and genetics of
thyroid carcinoma. J Surg Oncol. 94:662–669. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu T, You X, Sui J, Shen B, Zhang Y,
Zhang XM, Yang S, Yao YZ, Yang F, Yin LH, et al: Prognostic value
of a two-microRNA signature for papillary thyroid cancer and a
bioinformatic analysis of their possible functions. J Cell Biochem.
Nov 2–2018.(Epub ahead of print). doi: 10.1002/jcb.27993 2018.
|
|
14
|
Wang X, Huang S, Li X, Jiang D, Yu H, Wu
Q, Gao C and Wu Z: A potential biomarker hsa-miR-200a-5p
distinguishing between benign thyroid tumors with papillary
hyperplasia and papillary thyroid carcinoma. PLoS One.
13:e02002902018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vuong HG, Altibi AM, Abdelhamid AH, Ngoc
PU, Quan VD, Tantawi MY, Elfil M, Vu TL, Elgebaly A, Oishi N, et
al: The changing characteristics and molecular profiles of
papillary thyroid carcinoma over time: A systematic review.
Oncotarget. 8:10637–10649. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tricoli JV and Jacobson JW: MicroRNA:
Potential for Cancer Detection, Diagnosis, and Prognosis. Cancer
Res. 67:4553–4555. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Boufraqech M, Klubo-Gwiezdzinska J and
Kebebew E: MicroRNAs in the thyroid. Best Pract Res Clin Endocrinol
Metab. 30:603–619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Macha MA, Seshacharyulu P, Krishn SR, Pai
P, Rachagani S, Jain M and Batra SK: MicroRNAs (miRNAs) as
biomarker(s) for prognosis and diagnosis of gastrointestinal (GI)
cancers. Curr Pharm Des. 20:5287–5297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Parvex P: Are microRNA potential
biomarkers in children with idiopathic nephrotic syndrome?
EBioMedicine. 39:27–28. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Farazi TA, Spitzer JI, Morozov P and
Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Yu X, Shen J, Law PT, Chan MT and Wu
WK: MicroRNA expression and its implications for diagnosis and
therapy of gallbladder cancer. Oncotarget. 6:13914–13921. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L, Peng M, Xue W, Fan Z, Wang T, Lian
J, Zhai Y, Lian W, Qin D and Zhao J: Integrated analysis of
dysregulated long non-coding RNAs/microRNAs/mRNAs in metastasis of
lung adenocarcinoma. J Transl Med. 16:3722018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma Y and Sun Y: miR-29a-3p inhibits
growth, proliferation, and invasion of papillary thyroid carcinoma
by suppressing NF-κB signaling via direct targeting of OTUB2.
Cancer Manag Res. 11:13–23. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Y, Ren F, Luo Y, Rong M, Chen G and
Dang Y: Down-Regulation of miR-193a-3p Dictates Deterioration of
HCC: A Clinical Real-Time qRT-PCR Study. Med Sci Monit.
21:2352–2360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chou NH, Lo YH, Wang KC, Kang CH, Tsai CY
and Tsai KW: miR-193a-5p and −3p Play a Distinct Role in Gastric
Cancer: miR-193a-3p Suppresses Gastric Cancer Cell Growth by
Targeting ETS1 and CCND1. Anticancer Res. 38:3309–3318. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang Y, Luo H, Li F, Yang Y, Ou G, Ye X
and Li N: LINC00152 down-regulated miR-193a-3p to enhance MCL1
expression and promote gastric cancer cells proliferation. Biosci
Rep. 38:BSR201716072018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Deng W, Yan M, Yu T, Ge H, Lin H, Li J,
Liu Y, Geng Q, Zhu M, Liu L, et al: Quantitative proteomic analysis
of the metastasis-inhibitory mechanism of miR-193a-3p in non-small
cell lung cancer. Cell Physiol Biochem. 35:1677–1688. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu M, Liu Z, Liu Y, Zhou X, Sun F, Liu Y,
Li L, Hua S, Zhao Y, Gao H, et al: PTP1B markedly promotes breast
cancer progression and is regulated by miR-193a-3p. FEBS J.
286:1136–1153. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Takahashi H, Takahashi M, Ohnuma S, Unno
M, Yoshino Y, Ouchi K, Takahashi S, Yamada Y, Shimodaira H and
Ishioka C: microRNA-193a-3p is specifically down-regulated and acts
as a tumor suppressor in BRAF-mutated colorectal cancer. BMC
Cancer. 17:7232017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mamoori A, Wahab R, Islam F, Lee K, Vider
J, Lu CT, Gopalan V and Lam AK: Clinical and biological
significance of miR-193a-3p targeted KRAS in colorectal cancer
pathogenesis. Hum Pathol. 71:145–156. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Santarpia L, Calin GA, Adam L, Ye L, Fusco
A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C, et al: A
miRNA signature associated with human metastatic medullary thyroid
carcinoma. Endocr Relat Cancer. 20:809–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao M, Xu P, Liu Z, Zhen Y, Chen Y, Liu
Y, Fu Q, Deng X, Liang Z, Li Y, et al: Dual roles of miR-374a by
modulated c-Jun respectively targets CCND1-inducing PI3K/AKT signal
and PTEN-suppressing Wnt/β-catenin signaling in non-small-cell lung
cancer. Cell Death Dis. 9:782018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li Y, Li D, Yang W, Fu H, Liu Y and Li Y:
Overexpression of the transcription factor FOXP3 in lung
adenocarcinoma sustains malignant character by promoting G1/S
transition gene CCND1. Tumour Biol. 37:7395–7404. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Z, Wang C, Prendergast GC and Pestell
RG: Cyclin D1 functions in cell migration. Cell Cycle. 5:2440–2442.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang H, Han Y, Yang X, Li M, Zhu R, Hu J,
Zhang X, Wei R, Li K and Gao R: HNRNPK inhibits gastric cancer cell
proliferation through p53/p21/CCND1 pathway. Oncotarget.
8:103364–103374. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xue J, Qin Z, Li X, Zhang J, Zheng Y, Xu
W, Cao Q and Wang Z: Genetic polymorphisms in cyclin D1 are
associated with risk of renal cell cancer in the Chinese
population. Oncotarget. 8:80889–80899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng S, Serra S, Mercado M, Ezzat S and
Asa SL: A high-throughput proteomic approach provides distinct
signatures for thyroid cancer behavior. Clin Cancer Res.
17:2385–2394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deng M, Brägelmann J, Schultze JL and
Perner S: Web-TCGA: An online platform for integrated analysis of
molecular cancer data sets. BMC Bioinformatics. 17:722016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chandran UR, Medvedeva OP, Barmada MM,
Blood PD, Chakka A, Luthra S, Ferreira A, Wong KF, Lee AV, Zhang Z,
et al: TCGA Expedition: A Data Acquisition and Management System
for TCGA Data. PLoS One. 11:e01653952016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets - update. Nucleic Acids Res 41D. D991–D995.
2013.
|
|
42
|
Lassalle S, Zangari J, Popa A, Ilie M,
Hofman V, Long E, Patey M, Tissier F, Belléannée G, Trouette H, et
al: MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of
vandetanib. Oncotarget. 7:30461–30478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Minna E, Romeo P, Dugo M, De Cecco L,
Todoerti K, Pilotti S, Perrone F, Seregni E, Agnelli L, Neri A, et
al: miR-451a is underexpressed and targets AKT/mTOR pathway in
papillary thyroid carcinoma. Oncotarget. 7:12731–12747. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rossing M, Borup R, Henao R, Winther O,
Vikesaa J, Niazi O, Godballe C, Krogdahl A, Glud M, Hjort-Sørensen
C, et al: Down-regulation of microRNAs controlling tumourigenic
factors in follicular thyroid carcinoma. J Mol Endocrinol.
48:11–23. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ioannidis JP, Patsopoulos NA and Evangelou
E: Uncertainty in heterogeneity estimates in meta-analyses. BMJ.
335:914–916. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gan BL, He RQ, Zhang Y, Wei DM, Hu XH and
Chen G: Downregulation of HOXA3 in lung adenocarcinoma and its
relevant molecular mechanism analysed by RT-qPCR, TCGA and in
silico analysis. Int J Oncol. 53:1557–1579. 2018.PubMed/NCBI
|
|
47
|
Deng Y, He R, Zhang R, Gan B, Zhang Y,
Chen G and Hu X: The expression of HOXA13 in lung adenocarcinoma
and its clinical significance: A study based on The Cancer Genome
Atlas, Oncomine and reverse transcription-quantitative polymerase
chain reaction. Oncol Lett. 15:8556–8572. 2018.PubMed/NCBI
|
|
48
|
Liang YY, Huang JC, Tang RX, Chen WJ, Chen
P, Cen WL, Shi K, Gao L, Gao X, Liu AG, et al: Clinical value of
miR-198-5p in lung squamous cell carcinoma assessed using
microarray and RT-qPCR. World J Surg Oncol. 16:222018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bardou P, Mariette J, Escudié F, Djemiel C
and Klopp C: jvenn: An interactive Venn diagram viewer. BMC
Bioinformatics. 15:2932014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
The Gene Ontology Consortium, . The Gene
Ontology Resource: 20 years and still GOing strong. Nucleic Acids
Res. 47(D1): D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kanehisa M, Sato Y, Furumichi M, Morishima
K and Tanabe M: New approach for understanding genome variations in
KEGG. Nucleic Acids Res 47D. D590–D595. 2019. View Article : Google Scholar
|
|
53
|
Schriml LM, Mitraka E, Munro J, Tauber B,
Schor M, Nickle L, Felix V, Jeng L, Bearer C, Lichenstein R, et al:
Human Disease Ontology 2018 update: Classification, content and
workflow expansion. Nucleic Acids Res 47D. D955–D962. 2019.
View Article : Google Scholar
|
|
54
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wickham H: ggplot2: Elegant Graphics for
Data Analysis. Springer; New York, NY: 2016
|
|
56
|
Szklarczyk D, Gable AL, Lyon D, Junge A,
Wyder S, Huerta-Cepas J, Simonovic M, Doncheva NT, Morris JH, Bork
P, et al: STRING v11: Protein-protein association networks with
increased coverage, supporting functional discovery in genome-wide
experimental datasets. Nucleic Acids Res 47D. D607–D613. 2019.
View Article : Google Scholar
|
|
57
|
Vasko V, Espinosa AV, Scouten W, He H,
Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la
Chapelle A, et al: Gene expression and functional evidence of
epithelial-to-mesenchymal transition in papillary thyroid carcinoma
invasion. Proc Natl Acad Sci USA. 104:2803–2808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Fontaine JF, Mirebeau-Prunier D, Franc B,
Triau S, Rodien P, Houlgatte R, Malthièry Y and Savagner F:
Microarray analysis refines classification of non-medullary thyroid
tumours of uncertain malignancy. Oncogene. 27:2228–2236. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Salvatore G, Nappi TC, Salerno P, Jiang Y,
Garbi C, Ugolini C, Miccoli P, Basolo F, Castellone MD, Cirafici
AM, et al: A cell proliferation and chromosomal instability
signature in anaplastic thyroid carcinoma. Cancer Res.
67:10148–10158. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Giordano TJ, Au AY, Kuick R, Thomas DG,
Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, et
al: Delineation, functional validation, and bioinformatic
evaluation of gene expression in thyroid follicular carcinomas with
the PAX8-PPARG translocation. Clin Cancer Res. 12:1983–1993. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dom G, Tarabichi M, Unger K, Thomas G,
Oczko-Wojciechowska M, Bogdanova T, Jarzab B, Dumont JE, Detours V
and Maenhaut C: A gene expression signature distinguishes normal
tissues of sporadic and radiation-induced papillary thyroid
carcinomas. Br J Cancer. 107:994–1000. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Handkiewicz-Junak D, Swierniak M, Rusinek
D, Oczko-Wojciechowska M, Dom G, Maenhaut C, Unger K, Detours V,
Bogdanova T, Thomas G, et al: Gene signature of the post-Chernobyl
papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 43:1267–1277.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Barros-Filho MC, Marchi FA, Pinto CA,
Rogatto SR and Kowalski LP: High Diagnostic Accuracy Based on
CLDN10, HMGA2, and LAMB3 Transcripts in Papillary Thyroid
Carcinoma. J Clin Endocrinol Metab. 100:E890–E899. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Pita JM, Figueiredo IF, Moura MM, Leite V
and Cavaco BM: Cell cycle deregulation and TP53 and RAS mutations
are major events in poorly differentiated and undifferentiated
thyroid carcinomas. J Clin Endocrinol Metab. 99:E497–E507. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Pita JM, Banito A, Cavaco BM and Leite V:
Gene expression profiling associated with the progression to poorly
differentiated thyroid carcinomas. Br J Cancer. 101:1782–1791.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Rusinek D, Swierniak M, Chmielik E, Kowal
M, Kowalska M, Cyplinska R, Czarniecka A, Piglowski W, Korfanty J,
Chekan M, et al: BRAFV600E-Associated Gene Expression Profile:
Early Changes in the Transcriptome, Based on a Transgenic Mouse
Model of Papillary Thyroid Carcinoma. PLoS One. 10:e01436882015.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
von Roemeling CA, Marlow LA, Pinkerton AB,
Crist A, Miller J, Tun HW, Smallridge RC and Copland JA: Aberrant
lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl
CoA desaturase 1 as a novel therapeutic target. J Clin Endocrinol
Metab. 100:E697–E709. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Liu J, Xu J, Li H, Sun C, Yu L, Li Y, Shi
C, Zhou X, Bian X, Ping Y, et al: miR-146b-5p functions as a tumor
suppressor by targeting TRAF6 and predicts the prognosis of human
gliomas. Oncotarget. 6:29129–29142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xiong DD, Li ZY, Liang L, He RQ, Ma FC,
Luo DZ, Hu XH and Chen G: The LncRNA NEAT1 Accelerates Lung
Adenocarcinoma Deterioration and Binds to Mir-193a-3p as a
Competitive Endogenous RNA. Cell Physiol Biochem. 48:905–918. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Uhlén M, Fagerberg L, Hallström BM,
Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C,
Sjöstedt E, Asplund A, et al: Proteomics. Tissue-based map of the
human proteome. Science. 347:12604192015. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Kitahara CM and Sosa JA: The changing
incidence of thyroid cancer. Nat Rev Endocrinol. 12:646–653. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Vigneri R, Malandrino P and Vigneri P: The
changing epidemiology of thyroid cancer: Why is incidence
increasing? Curr Opin Oncol. 27:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Raue F and Frank-Raue K: Thyroid Cancer:
Risk-Stratified Management and Individualized Therapy. Clin Cancer
Res. 22:5012–5021. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Qiu J, Zhang W, Zang C, Liu X, Liu F, Ge
R, Sun Y and Xia Q: Identification of key genes and miRNAs markers
of papillary thyroid cancer. Biol Res. 51:452018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Nixon AM, Provatopoulou X, Kalogera E,
Zografos GN and Gounaris A: Circulating thyroid cancer biomarkers:
Current limitations and future prospects. Clin Endocrinol (Oxf).
87:117–126. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Zhang Y, Pan J, Xu D, Yang Z, Sun J, Sun
L, Wu Y and Qiao H: Combination of serum microRNAs and ultrasound
profile as predictive biomarkers of diagnosis and prognosis for
papillary thyroid microcarcinoma. Oncol Rep. 40:3611–3624.
2018.PubMed/NCBI
|
|
78
|
Nikiforov YE: Role Of Molecular Markers In
Thyroid Nodule Management: Then And Now. Endocr Pract. 23:979–988.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Grossi I, Salvi A, Abeni E, Marchina E and
De Petro G: Biological Function of MicroRNA193a-3p in Health and
Disease. Int J Genomics. 2017:59131952017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Pekow J, Meckel K, Dougherty U, Huang Y,
Chen X, Almoghrabi A, Mustafi R, Ayaloglu-Butun F, Deng Z, Haider
HI, et al: miR-193a-3p is a Key Tumor Suppressor in Ulcerative
Colitis-Associated Colon Cancer and Promotes Carcinogenesis through
Upregulation of IL17RD. Clin Cancer Res. 23:5281–5291. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Fan Q, Hu X, Zhang H, Wang S, Zhang H, You
C, Zhang CY, Liang H, Chen X and Ba Y: miR-193a-3p is an Important
Tumour Suppressor in Lung Cancer and Directly Targets KRAS. Cell
Physiol Biochem. 44:1311–1324. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ren F, Ding H, Huang S, Wang H, Wu M, Luo
D, Dang Y, Yang L and Chen G: Expression and clinicopathological
significance of miR-193a-3p and its potential target astrocyte
elevated gene-1 in non-small lung cancer tissues. Cancer Cell Int.
15:802015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Williams M, Kirschner MB, Cheng YY, Hanh
J, Weiss J, Mugridge N, Wright CM, Linton A, Kao SC, Edelman JJ, et
al: miR-193a-3p is a potential tumor suppressor in malignant
pleural mesothelioma. Oncotarget. 6:23480–23495. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Lin M, Duan B, Hu J, Yu H, Sheng H, Gao H
and Huang J: Decreased expression of miR-193a-3p is associated with
poor prognosis in colorectal cancer. Oncol Lett. 14:1061–1067.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu Y, Xu X, Xu X, Li S, Liang Z, Hu Z, Wu
J, Zhu Y, Jin X, Wang X, et al: MicroRNA-193a-3p inhibits cell
proliferation in prostate cancer by targeting cyclin D1. Oncol
Lett. 14:5121–5128. 2017.PubMed/NCBI
|
|
86
|
Liang W and Sun F: Identification of key
genes of papillary thyroid cancer using integrated bioinformatics
analysis. J Endocrinol Invest. 41:1237–1245. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Jeon S, Kim Y, Jeong YM, Bae JS and Jung
CK: CCND1 Splice Variant as A Novel Diagnostic and Predictive
Biomarker for Thyroid Cancer. Cancers (Basel). 10:4372018.
View Article : Google Scholar
|
|
88
|
Lamba Saini M, Weynand B, Rahier J, Mourad
M, Hamoir M and Marbaix E: Cyclin D1 in well differentiated thyroid
tumour of uncertain malignant potential. Diagn Pathol. 10:322015.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Tsai KW, Leung CM, Lo YH, Chen TW, Chan
WC, Yu SY, Tu YT, Lam HC, Li SC, Ger LP, et al: Arm Selection
Preference of MicroRNA-193a Varies in Breast Cancer. Sci Rep.
6:281762016. View Article : Google Scholar : PubMed/NCBI
|
